Podcasts about Surpass

Jeremiah Sirles, Alex Boone and Phil Mackey react to Week 1 in the NFL! The Buffalo Bills, Green Bay Packers and Los Angeles Chargers all made BIG statements in Week 1! 00:00 - What a Week 1 in the NFL! The boys are fired up! 05:00 - We had a classic Sunday Night Football Game between the Buffalo Bills and Baltimore Ravens! What did the epic Bills' comeback teach us about both teams? 18:00 - The Los Angeles Chargers sent a major message to the Kansas City Chiefs in a loaded AFC West; Trouble in Kansas City? 24:00 - Should the Kansas City Chiefs trade for Tyreek Hill? 29:00 - Jeremiah demands an apology for Daniel Jones' historic performance in the Indianapolis Colts' blowout win over the Miami Dolphins 33:00 - Justin Fields and Aaron Rodgers both looked awesome in the Pittsburgh Steelers' win over the New York Jets; Is Aaron Rodgers capable of leading the Steelers to a deep playoff run? 43:00 - The Green Bay Packers are a legit NFC contender, and they showed why in a win over the Detroit Lions… Is it too early to panic about the Lions' offensive line? 54:00 - Should the New York Giants already consider starting Jaxson Dart at QB? 60:00 - The Dallas Cowboys are better than people think 66:00 - Reacting to a damning article about Chicago Bears' QB Caleb Williams 71:00 - Fat Guy Fantasy Draft, 2025! See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

8-9am Hour 3 - Joe DiBiase talks with Jay Binkley about the Kansas City Chiefs offseason. They talk about if the team can recover from their bad loss in the Super Bowl to the Eagles, the Rashee Rice suspension, and if the Chiefs are moving to the next part of their dynasty. Joe also dives into the crazy world of the Dallas Cowboys and Jerry Jones. He talks about Jones' comments about Micah Parsons and why Jones will eventually lose Parsons.

Send us a textOur Patreon - https://www.patreon.com/HockeyCardsGongshowOn this episode of the Hockey Cards Gongshow podcast we start with Get To Know Your Hockey Hall of Famers, this time looking at the life, hockey career, and hobby market for hockey hall of famer, Billy Gilmour (6:48).  In hobby news, eBay announces new selling tools, digital repacks are now a thing, Sergei Fedorov to have his number retired, and the Canadian hockey radio apocalypse (15:50).  We continue our series on top selling hockey players on eBay with the Top 10 and ask will any player ever surpass Wayne Gretzky's hockey cards market (1:06:14)? New new product releases we take an early look at the card designs for 2025-26 O-Pee-Chee (1:40:28), and end the show with personal pickups (1:52:35).Partners & SponsorsHockeyChecklists.com - https://www.hockeychecklists.comSlab Sharks Consignment - http://bit.ly/3GUvsxNSlab Sharks is now accepting U.S. submissions!MINTINK - https://www.mintink.caPSA - https://www.psacard.comGP Sports Cards - https://gpsportcards.com/Private Collection Insurance - https://privatecollectioninsurance.comPather Ultimate HoldersShop USA - https://shoppather.com/Shop Canada - https://shoppather.ca/Sign up for Card Ladder - https://app.cardladder.com/signup?via=HCGongshoFollow Hockey Cards Gongshow on social mediaInstagram - https://www.instagram.com/hockey_cards_gongshow/TikTok - https://www.tiktok.com/@hockey_cards_gongshowFacebook - https://www.facebook.com/HockeyCardsGongshowTwitter - https://twitter.com/HCGongshowThe Hockey Cards Gongshow podcast is a production of Dollar Box Ventures LLC

6-7am Hour 1 - Joe DiBiase and Nate Geary talk about the relevance of buffets in America today and also play some starting quarterback trivia. Joe and Nate also talk with Brian Koziol about the start of the PGA Tour Championship. They discuss Scottie Scheffler's dominance, who could win it all, and the Ryder Cup Rosters.

In this episode, Joel W. Cade and John Suchan discuss various topics, including the current state of the WNBA, insights from Myles Garrett's press conference, and the dynamics of the Browns' quarterback situation. They analyze the performances of Dillon Gabriel and Shedeur Sanders, and share their thoughts on the Ravens' 30-year anniversary celebration. The conversation wraps up with expectations for the upcoming preseason game. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of Don't Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Darren McGuire, MD, to explore the groundbreaking results of the SURPASS-CVOT trial. This cardiovascular outcome study is the first to directly compare two incretin-based therapies—tirzepatide, a dual GIP/GLP-1 receptor agonist, and dulaglutide, a GLP-1 receptor agonist—among patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). Unlike the placebo-controlled GLP-1 programs of the past decade, SURPASS-CVOT represents a pivotal move toward active comparator trials in cardiometabolic medicine. 00:00:00 Intro 00:01:35 Behind the trial 00:04:35 What is imputed placebo? 00:08:32 The size and scope of SURPASS-CVOT 00:11:01 Results of SURPASS-CVOT 00:14:20 How to select comparators among obesity medicines 00:17:37 Future trials 00:18:56 Interpreting these new kinds of comparisons 00:20:50 Active comparators are the future 00:24:01 Closing

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Today, we're diving into one of the most talked-about topics in health and weight loss right now: GLP-1 medications like semaglutide and the newer dual GIP/GLP-1s like tirzepatide. You've probably seen the headlines, scrolled past a few TikToks, or heard a friend mention it — but with all that noise comes a lot of confusion, half-truths, and flat-out myths. Today we're breaking it all down. What's real? What's hype? And what do you actually need to know if you're using these medications — or thinking about it? Let's separate science from scare tactics and get to the truth, one myth at a time. Myth #1: GLP-1s Cause Dangerous Muscle Loss The claim:  “GLP-1s cause massive muscle loss.” Truth: This is an overstatement. Some loss of lean mass is normal with any kind of weight loss — whether it's through diet, medication, or surgery. What studies show is that with medications like semaglutide (Wegovy) and tirzepatide (Zepbound), about 20–25% of the total weight lost comes from lean mass, and the rest is fat — which is exactly what we're targeting in obesity treatment. That 20–25% figure isn't unique to these meds; it's actually pretty typical in weight loss without focused resistance training or optimized protein intake. You may also hear “You'll lose all your muscle and become frail on GLP-1s.” Truth: You won't “lose all your muscle.” In fact, muscle loss is preventable by maintaining adequate protein intake, resistance training, and managing weight loss pace. Furthermore, many patients gain strength and mobility as excess weight comes off. And lastly, my favorite myth is “You can't preserve muscle on GLP-1s.” Truth: That's completely false — muscle loss isn't inevitable on GLP-1s if you take the right approach. You can absolutely preserve muscle by making a few intentional choices: aim for enough protein each day (a good goal is around 0.8 grams per pound of body weight), include some strength or resistance training a couple times a week, and avoid losing weight too quickly. These simple steps go a long way in protecting your lean mass while still getting all the benefits of weight loss. One study on semaglutide showed that people lost an average of about 15% of their body weight, and only around 3–4% of that was lean mass. So if someone drops 30 pounds, maybe 6 to 8 of those pounds might be lean mass—not ideal, but definitely not disastrous either, and very manageable with the right lifestyle habits.  The truth is, while some lean mass loss is expected with any type of weight loss, research shows that most of the weight lost on GLP-1s is actually fat, not muscle. For example, in the STEP 1 trial, about 80% of the weight lost on semaglutide came from fat, and only about 20% from lean tissue (as we mentioned earlier).  The SURMOUNT-1 trial with tirzepatide showed similar results—significant fat loss with relatively preserved muscle, especially when paired with resistance training. And that's important, because preserving muscle during weight loss helps protect metabolism, strength, and overall health. With good nutrition and movement, GLP-1s can lead to healthier body composition—not just a lower number on the scale. Okay, moving along to the next myth … Myth #2: GLP-1s Can Cause Blindness The truth: This myth stems from concerns about diabetic retinopathy worsening, which is tied to how quickly blood sugar drops, not to the drug itself. In the SUSTAIN-6 trial (Marso et al., NEJM, 2016), a small subset of patients with pre-existing advanced diabetic retinopathy saw transient worsening—but only in those with rapid improvements in A1c. No increased rates of blindness or new-onset retinopathy have been found in non-diabetic patients using GLP-1s for weight loss. The bottom line is that those without advanced diabetic eye disease, there's no increased risk of blindness. Patients with diabetic retinopathy should be monitored closely—but this is about glycemic management, not a direct effect of the medication. Myth #3: GLP-1s Cause Kidney or Liver Damage The truth: This is false. In fact, GLP-1 agonists may protect kidney and liver function—especially in patients with diabetes or fatty liver disease. The most recent notable study showing kidney‑protective effects of a GLP‑1 receptor agonist is the FLOW trial, which evaluated semaglutide in people with type 2 diabetes and chronic kidney disease (CKD). This double‑blind, randomized, placebo‑controlled trial included 3,533 participants followed for a median of 3.4 years and found that semaglutide reduced the risk of major kidney‑related events—including kidney failure, substantial eGFR decline, and death from renal or cardiovascular causes—by 24% compared to placebo. A 2025 meta-analysis of multiple randomized controlled trials (11 studies, 85,373 participants) concluded that GLP‑1 receptor agonists reduced the risk of composite kidney failure outcomes by 18%, kidney failure by 16%, and all‑cause death by 12%. And let's not forget the SMART trial, involving obese patients with kidney disease but without diabetes, found that semaglutide protected kidney function in this non‑diabetic, CKD‑affected population.  When it comes to the liver, there's actually growing evidence they're actually helping reverse non-alcoholic fatty liver disease (NAFLD). The STEP 1 MRI substudy and SURPASS-3 MRI substudy have shown people on these medications can reduce liver fat by 30 to even 50% and in some cases, completely resolve liver inflammation — that more serious form called NASH, where fat is combined with inflammation and early scarring. The LEAN trial found that nearly 60% of people taking semaglutide had resolution of NASH, without worsening their liver scarring. That's huge. And even better, we're seeing these effects even in people who don't have diabetes. Just losing weight helps fatty liver, but these meds seem to do more than that — they actually target inflammation and fat storage in the liver itself.. The bottom line is GLP-1s are not nephrotoxic or hepatotoxic. In fact, they may be organ-protective—especially for people with underlying metabolic issues. Myth #4: These Drugs Lead to Bone Loss The claim: “You'll get osteoporosis from losing too much weight!” The truth: While extreme weight loss can affect bone density, GLP-1s themselves do not cause bone loss, and may even have neutral or protective effects on bone. A 2022 study in Bone found no significant change in BMD (bone mineral density) in adults treated with semaglutide for obesity. While the SUSTAIN and PIONEER programs found no increased risk of fractures in semaglutide-treated patients versus placebo. Truly, concerns about bone loss are more relevant in extreme calorie restriction or eating disorders—not evidence-based GLP-1 treatment with appropriate nutrition. Myth #5: Everyone Gets Gastroparesis The claim: “These medications paralyze your stomach” The truth: GLP-1s slow gastric emptying, which is part of how they work—making you feel full longer. But this is dose-dependent and typically reversible. A 2023 FDA safety review found that true gastroparesis is extremely rare and resolves when the drug is stopped. Reality check: Nausea, early satiety, and mild bloating are common but manageable side effects. True, lasting gastroparesis is not typical, especially when doses are titrated gradually. Myth #6: GLP-1s Make Your Hair Fall Out The claim: “You'll lose a ton of hair—just like with crash diets” The truth: Hair shedding is not directly caused by GLP-1 medications. Instead, it's often a temporary, non-scarring condition called telogen effluvium, which can happen with any rapid weight loss, regardless of the method. A 2023 analysis from the American Academy of Dermatology emphasized that telogen effluvium is common with surgical or medical weight loss, especially if patients lose more than 10% of their body weight within a few months. In clinical trials like STEP and SURMOUNT, hair loss was not listed as a common side effect, but patient-reported data show it occurs occasionally—likely tied to nutritional stress, not the drug itself. So why does hair loss happen? We've talked about this before, but I don't want to leave this important information out.  Hair follicles are sensitive to internal stress. Rapid changes in caloric intake, nutrient levels (like iron, zinc, and biotin), or hormone balance can push hairs into the shedding phase. This is a delayed effect, often showing up 2–3 months after weight loss begins, and it typically resolves within 6–12 months. What helps is slower, sustained weight loss, prioritizing protein intake, supplementing iron, zinc, and biotin if deficient, and avoiding very low-calorie diets and over-restriction. Myth #6: GLP-1s Cause Dehydration It's a common myth that GLP-1 medications cause dehydration — but that's not exactly true. The medication itself doesn't directly dehydrate you. What can happen is that some people experience nausea, vomiting, or a reduced appetite early on, which can lead to drinking less water without realizing it. That's where the dehydration risk comes in. A good general rule for staying hydrated is to aim for half your body weight in ounces of water per day. So, for example, if you weigh 160 pounds, try to drink around 80 ounces daily — more if you're active or live in a hot climate. Electrolytes can also be really helpful, especially if you're feeling tired, dizzy, or crampy. I like LMNT packets — they're a clean option with no sugar and a good balance of sodium, magnesium, and potassium. The sodium in LMNT packets helps keep you hydrated by pulling water into your cells and helping your body retain the fluids it needs to function properly. Just one a day can make a big difference in how you feel. Myth #7: You Have to Stay on GLP-1s Forever or You'll Gain All the Weight Back The claim: “As soon as you stop taking it, all the weight comes back” The truth: Yes—some weight regain is likely after stopping GLP-1 medications. But that doesn't mean they're ineffective or that you're doomed to rebound completely. The same pattern happens after any type of weight loss intervention, whether it's a diet, surgery, or medication. The STEP 4 trial (Wilding et al., 2022) showed that participants who stopped semaglutide after 20 weeks regained an average of 6% of their weight loss over the next year. But it's important to note that they still weighed less than at baseline—and many continued to experience improvements in blood pressure, cholesterol, and insulin sensitivity. Similarly, in SURMOUNT-4, patients who stopped tirzepatide also regained weight, but less than they lost. So why does this weight gain happen? I feel like the answer to this is obvious, but I've found that it's not.  GLP-1s change your appetite and hunger cues. Once the medication is stopped, your body's baseline hunger signals return—and often with increased intensity, due to metabolic adaptation. But this isn't unique to GLP-1s. The same thing happens after crash diets, keto, intermittent fasting, or bariatric surgery if long-term changes aren't made. The real issue isn't the drug—it's the lack of a plan after the drug. To help make results sustainable, we need to use the medication as a tool, not a crutch. We should use it to help us lose weight and understand our hunger cues, while transitioning to a whole foods, protein based diet coupled with resistance training to help preserve and build muscle.  Just remember, if you're coming off a GLP-1 and want to keep the momentum going, the key is to approach it thoughtfully. Tapering slowly under medical supervision can help your body adjust and reduce the chances of weight regain. At the same time, this is a great moment to double down on the habits that helped you feel your best while on the medication. Think ongoing support—like working with a health coach, joining a support group, or even doing behavioral therapy—to help reinforce those long-term lifestyle changes. It's not just about what you stop; it's about what you keep doing that matters most. You don't necessarily have to stay on GLP-1s forever—but if you stop without a plan, some weight regain is very likely. Think of them like glasses: they help you see clearly while you build the habits to eventually navigate without them. For some, that may mean staying on a lower maintenance dose long-term—just like with blood pressure or cholesterol meds. What are my final thoughts? I want to be clear—GLP-1s aren't magic. But they are powerful tools when paired with education, support, and smart lifestyle changes.  Myths like ‘you'll go blind,' ‘you'll lose all your hair,' or ‘you'll be stuck on these meds forever' aren't just misleading and downright false—they discourage people from getting real help.  So if you're thinking about these medications, get informed, ask the hard questions, and make your decision based on science—not fear. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

(00:00) Zolak & Bertrand start the second hour discussing the Patriots upcoming preseason game and Mike Vrabel saying everyone who is healthy should expect to play; The guys debate if Drake Maye should risk playing or not. (9:28) The crew discusses the conversation of Drake Maye vs. Jayden Daniels after the two went head-to-head at practice on Wednesday. (21:36) The guys finish the hour discussing more on the Patriots and the upcoming ceremony for the Tom Brady statue. (34:18) We finish the hour playing This or That! This episode of Zolak & Bertrand is brought to you in part by Profluent. https://go.happinessexperiment.com/begin-aff-o1-page2-107890-365938?am_id=podcast2025&utm_source=podcast&utm_medium=podcast&utm_campaign=michael

The boys are BACK this week on ARG Presents! We spun the wheel and made the deal for ROM HACKS this week! First we'll discuss the merits and flaws of ROM hacks, and then it's GAME TIME! Do these choices surpass the games they are based on, or is it a ROM MESS! FIND OUT as we take on Super Mario 6 on the Nintendo Entertainment System (NES) and Teenage Mutant Ninja Turtles Shredder's Re-Revenge on the Megadrive / Genesis!

The boys are BACK this week on ARG Presents! We spun the wheel and made the deal for ROM HACKS this week! First we'll discuss the merits and flaws of ROM hacks, and then it's GAME TIME! Do these choices surpass the games they are based on, or is it a ROM MESS! FIND OUT as we take on Super Mario 6 on the Nintendo Entertainment System (NES) and Teenage Mutant Ninja Turtles Shredder's Re-Revenge on the Megadrive / Genesis!

On July 31, 2025, Eli Lilly and Company announced topline data from the SURPASS‑CVOT trial comparing tirzepatide (Mounjaro) to dulaglutide (Trulicity) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). According to the data, tirzepatide met the primary non‑inferiority endpoint for 3-point major adverse cardiovascular events (MACE) (hazard ratio [HR], 0.92; 95.3% CI, 0.83 to 1.01), while also showing additional benefits in A1C, weight reduction, renal preservation, and a 16% reduction in all‑cause mortality (HR, 0.84; 95.0% CI, 0.75 to 0.94). In the latest episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, unpacked the top-line results of the SURPASS-CVOT trial. Eli Lilly and Company owns both drugs, which belong to the incretin class, but tirzepatide is a dual GIP/GLP-1 receptor agonist, while dulaglutide is a GLP-1 RA. The trial included over 13,000 adults with type 2 diabetes and either established cardiovascular disease or at high risk. During a median follow-up of 4.5 years, the primary endpoint, which was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, was reduced by 8% in the tirzepatide group relative to dulaglutide. However, the result did not reach statistical superiority due to the confidence interval crossing unity. Isaacs and Bellini also highlighted significantly greater A1c (-1.73% vs -0.9%) and weight loss (12% vs 4.95%) with tirzepatide. Additional prespecified analyses comparing data with the placebo-controlled REWIND trial suggest tirzepatide could offer up to 28% MACE and 39% mortality risk reduction compared to theoretical placebo—findings that hint at broader cardiometabolic benefit. Before concluding, hosts speculated about the potential subgroup analyses of interest for the trial, including heart failure and renal outcomes, as well as a brief discussion around Eli Lilly and Company's intent to submit a regulatory application for a cardiovascular indication before the close of 2025. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Eli Lilly and Company. Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. July 31, 2025. Accessed July 31, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated

An eventful Thursday full of goodies and featuring Three Plates Tommy.Three Plates Tommyhttps://www.instagram.com/holdingitdownwith3plates/E-Zonehttp://flavorsbyezone.comChicletshttps://www.instagram.com/chiclets_los.angeles/

Helena Wang, Research Analyst at Phillip Securities Research, will cover our second quarter 2025 earnings report on Netflix Incorporated, titled “Tough to surpass high expectations”.Listen to this podcast to stay updated on the latest corporate news. Additionally, you can visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.poems.com.sg/stock-research⁠⁠⁠ to access the full report and gain more insights.#PhillipCapital #YourPartnerinFinance #Servingyousince1975  #FinTech #PYTCH #PYTCHMedia #USCompanyInsights #FinanceNews #US #Netflix #NFLXFollow PYTCH Media:⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠

Authorities expect China's total tax revenue to surpass 85 trillion yuan during the 14th Five-Year Plan period, marking an increase of 13 trillion yuan compared to the previous five-year period.

In the SCENT trial, researchers investigated the effects of the Surpass flow diverter system for treating wide-necked aneurysms. Five-year results of this trial have recently been published in JNIS, presenting the safety and effectiveness outcomes of treatment with the Surpass Streamline flow diverter system. The study analyses the rates of aneurysm occlusion and adverse events.   Editor-in-Chief of JNIS, Dr. Felipe C. Albuquerque, interviews Dr. Philip Meyers¹, author of the paper: Five-year results of the SCENT trial with Surpass flow diverters to treat large or giant wide-neck aneurysms   1. Radiology and Neurological Surgery, Columbia University, New York, USA   Please subscribe to the JNIS podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/4aZmlpT) or Spotify (https://spoti.fi/3UKhGT5). We'd love to hear your feedback on social media - @JNIS_BMJ.

Nick and Jake continue their conversation on how Patrick Mahomes can be surpassed as the best QB in the NFL.

Nick and Jake talk about how Patrick Mahomes can be surpassed as the best QB in the NFL. Then, they're joined by Jake Murren as they go through trade ideas for the Guardians.

Basic Cryptonomics 101: What The FSCK Is Davinci Jeremie On About? #Crypto #Cryptocurrency #podcast #BasicCryptonomics #Bitcoin #Ethereum   Website: ⁠⁠⁠⁠https://www.CryptoTalkRadio.net⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠@ThisIsCTR⁠⁠⁠⁠ Discord:⁠⁠⁠⁠ @CryptoTalkRadio⁠⁠⁠⁠ Chapters (00:00:01) - Crypto Talk Radio(00:02:13) - Ethereum vs. Bitcoin: When Will it Surpass?(00:09:46) - Are Crypto Laws Necessary?(00:12:04) - Da Vinci Jeremy: Why Should You Buy Bitcoin?(00:19:26) - Jeremy Polsky: A World Without a Fiat Currency

Dr. Craig Jenne is a professor of microbiology, immunology and infectious diseases at the University of Calgary Learn more about your ad choices. Visit megaphone.fm/adchoices

SBWCam Roigard is helping revolutionise the All Blacks attack, with a greater focus on his sniping play. We ask whether he'll dethrone Du Pont and JGP as the world's best.SBW joins us to talk his fight against Paul Gallen this week.We break down how the Springboks' epic new tricks plays work and their effects on defense, as well as the evolution of the Boks' back play.We ask where wonderkid Henry Pollock will play in the first test for the Lions against Australia Hosted on Acast. See acast.com/privacy for more information.

In this week's episode of the Coin Stories News Block powered exclusively by Ledn, we cover the biggest headlines related to Bitcoin, macroeconomics, and global finance: Bitcoin Breaks $120,000, Expert Predicts $200K in 2025 IBIT: Fastest ETF to $80 Billion It's “Crypto Week” in the U.S. -- What That Means for Regulatory Clarity Bitcoin Advocate Gould Confirmed as New OCC Chief ---- The News Block is powered exclusively by Ledn – the global leader in Bitcoin-backed loans, issuing over $9 billion in loans since 2018, and they were the first to offer proof of reserves. With Ledn, you get custody loans, no credit checks, no monthly payments, and more. Learn more at www.Ledn.io ---- Read every story in the News Block with visuals and charts! Join our mailing list and subscribe to our free Bitcoin newsletter: https://thenewsblock.substack.com   ---- References mentioned in the episode: Bitcoin Hits New All-Time Highs Trump Issues New Tariffs on Trade Partners Trump Announces Sweeping New Tariffs  A Significant Number of Shorts Were Liquidated  Michael Saylor Tweet on Shorting Bitcoin Bitcoin Was the Best-Performing Asset Class in Q2 Central Banks Cutting Rates at Fastest Pace since 2020 Central Banks Have Cut Rates 64 Times in 2025 White House “Looking Into” Trump's Ability to Fire Powell Bitcoin ETFs Set Second-Largest Daily Inflow  IBIT Becomes Fastest-Ever ETF to Surpass $80 Billion Matt Hougan's Tweet on Supply and Demand  Bitcointreasuries.net Chart Showing Institutional Adoption House Speaker Announces July 14 “Crypto Week” in D.C. Bo Hines' Tweet on “Crypto Week”  Senate Confirms Jonathan Gould as OCC HeadJPMorgan Tells Fintechs to Pay Up for Customer Data Access Former Bitfury Executive Gould to Take Over OCC ---- Natalie's Upcoming Events: Bitcoin 2026 will be here before you know it. Get 10% off Early Bird passes using the code HODL: https://tickets.b.tc/event/bitcoin-2026?promoCodeTask=apply&promoCodeInput=  Your Bitcoin oasis awaits at Camp Nakamoto: A retreat for Bitcoiners, by Bitcoiners. Code HODL for discounted passes: https://massadoptionbtc.ticketspice.com/camp-nakamoto      ---- This podcast is for educational purposes and should not be construed as official investment advice. ---- VALUE FOR VALUE — SUPPORT NATALIE'S SHOWS Strike ID https://strike.me/coinstoriesnat/ Cash App $CoinStories #money #Bitcoin #investing

Fluent Fiction - Japanese: Trusting Instincts: A Quest for the Perfect Tea in Shirakawago Find the full episode transcript, vocabulary words, and more:fluentfiction.com/ja/episode/2025-07-13-22-34-02-ja Story Transcript:Ja: 夏のある日、静かな山村、白川郷の伝統的な茶屋にケイコが訪れました。En: One summer day, Shirakawago, a quiet mountain village, Keiko visited a traditional teahouse.Ja: 白川郷は緑豊かな山々に囲まれた美しい場所でした。En: Shirakawago was a beautiful place surrounded by lush green mountains.Ja: 彼女は特別な緑茶を探していました。その茶を見つけて、おばあさんに喜んでもらいたいと願っていました。En: She was on a quest to find a special green tea; she wished to find this tea to bring joy to her grandmother.Ja: 茶屋の中は、様々なお茶の香りでいっぱいでした。En: Inside the teahouse, it was filled with the fragrance of various teas.Ja: 棚にはたくさんのラベル付きの瓶が並んでいました。En: Shelves were lined with many labeled jars.Ja: 優しそうな顔をしたお茶マスター、ヒロが近づいてきました。En: Hiro, the tea master with a kind-looking face, approached her.Ja: 「ケイコさん、お久しぶりですね。どうしましたか？」ヒロが言いました。En: "Keiko, it's been a while, hasn't it? What's brought you here?" Hiro asked.Ja: 「ヒロさん、お手伝いが必要です。おばあちゃんに特別な緑茶を見つけたいんです。でも、どれがいいのかわかりません」とケイコは不安そうに答えました。En: "Hiro, I need your help. I want to find a special green tea for my grandmother. But I don't know which one to choose," Keiko replied anxiously.Ja: ヒロは笑顔でうなずき、「ケイコさんの感性を信じることが大事ですよ。ここにヒントがあります」と小さな紙を渡しました。En: With a smile, Hiro nodded and said, "It's important to trust your own instincts, Keiko. Here's a hint," and handed her a small piece of paper.Ja: 紙に書かれていたのは「伝統を越え、直感を信じよ」というメッセージだけでした。ケイコはちょっと戸惑いましたが、茶屋の中を歩いてみることにしました。En: Written on the paper was just a message: "Surpass tradition and trust your intuition." Although a bit puzzled, Keiko decided to walk around the teahouse.Ja: 香りを嗅ぎ、茶の色を見比べました。En: She smelled the aromas and compared tea colors.Ja: その時、地元の不思議な人物、サトウがやってきました。En: At that moment, a mysterious local, Sato, appeared.Ja: 「秘密のお茶を探しているのか？」と問いかけてきました。En: "Are you searching for a secret tea?" he inquired.Ja: 彼は茶の秘密を知っていると主張しましたが、完全には信じられませんでした。En: He claimed to know the secrets of tea, but Keiko wasn't entirely convinced.Ja: ケイコはしばらく考えましたが、結局サトウには頼らず、自分の直感を信じることにしました。En: Keiko thought for a while but eventually decided not to rely on Sato and trusted her own intuition instead.Ja: ヒロさんの言葉を思い出し、再び茶棚の前に立ちました。En: Remembering Hiro's words, she stood again in front of the tea shelves.Ja: 突然、ある一瓶の茶が彼女に呼びかけるように見えました。En: Suddenly, one jar seemed to call out to her.Ja: 「これだ！」ケイコは心の中で叫びました。En: "This is it!" Keiko exclaimed in her heart.Ja: その瓶の中のお茶は美しく、深い香りがしました。En: The tea inside the jar was beautiful, and it had a deep fragrance.Ja: この緑茶こそが特別だと直感しました。En: She instinctively felt this green tea was special.Ja: その日の夕方、ケイコはお茶を持って帰り、おばあさんに差し出しました。En: That evening, Keiko returned home with the tea and offered it to her grandmother.Ja: タンバタの夜、おばあさんは茶を淹れてくれました。En: On the night of Tanabata, her grandmother brewed the tea.Ja: お茶を飲んだおばあさんの目に涙が浮かびました。En: Tears welled up in her grandmother's eyes as she drank it.Ja: 「ケイコ、これは本当に素晴らしい茶だね。あなたの努力と成長が感じられるよ」とおばあさんは優しく言いました。En: "Keiko, this tea is truly wonderful. I can feel your effort and growth," her grandmother said gently.Ja: ケイコは、自分の決断力と伝統への理解を信じることができました。En: Keiko was able to believe in her judgment and her understanding of tradition.Ja: タンバタの星空の下、二人はお茶を楽しみ、幸せな時を過ごしました。En: Under the Tanabata starlit sky, the two enjoyed the tea and spent a happy time together.Ja: これからは、ケイコは自信を持って自分の意見を大切にすることができました。En: From then on, Keiko could confidently cherish her own opinions. Vocabulary Words:quest: 探求fragrance: 香りshelves: 棚labeled: ラベル付きapproached: 近づいてきましたinstincts: 感性hint: ヒントsurpass: 越えintuition: 直感puzzled: 戸惑いましたmysterious: 不思議なlocal: 地元の人物inquired: 問いかけてきましたsecrets: 秘密convinced: 信じられませんでしたrely: 頼らずjudgment: 決断力cherish: 大切にするaromas: 香りcompared: 見比べましたinstinctively: 直感しましたbrewed: 淹れてくれましたwelled up: 涙が浮かびeffort: 努力growth: 成長understanding: 理解starlit: 星空の下confidently: 自信を持ってexclaimed: 叫びましたtraditional: 伝統的な

7.11.25 Mike Florio goes in-depth with the controversy on the name change of the Washington Commanders Who will be the most improved NFL coaches in 2025?

Subscribe to the #STTSportsNetwork and stay tuned for a video dropping on August 1st on how to enter a raffle for both a football autographed by Cooper Dejean and Darius Slay along with a framed photo of AJ Brown (all proceeds from raffle tix will be donated to Eagles Autism) https://youtube.com/@trendingintheam?si=IG7MG1N0lwc33pu- And Catch #TrendingintheAM daily at 8am! Learn more about your ad choices. Visit megaphone.fm/adchoices

Ethan Bratton, writer and reporter with KTRH Radio in Houston, reports on the Texas floods.

Today on America in the Morning  Texas Tragedy Now 100 Dead As the death toll now surpasses 100, the aftermath of deadly flooding in Texas is bringing political finger pointing in the Lone Star State and in Washington, while recovery operations continue to find those still missing.  Correspondent Clayton Neville reports.   Trump-Netanyahu Dinner Israeli Prime Minister Benjamin Netanyahu was in the Nation's Capital meeting with President Trump and top aides for dinner Monday night.  John Stolnis has more on what was said, from Washington.  Epstein Outrage There's outrage from some leading conservatives after reports that the Justice Department now acknowledges there is no Jeffrey Epstein 'client list,' placing Attorney General Pam Bondi under scrutiny.  Washington correspondent Sagar Meghani reports.    New Immigration Rules Immigration changes are coming for some Hondurans and Nicaraguans on Temporary Protection Status.  Correspondent Haya Panjwani reports.  Keep Your Shoes On The Transportation Security Administration is letting that rule expire for fliers going through the standard TSA screening procedures.      Trump On Tariffs President Donald Trump is threatening to significantly raise tariffs on seven trading partners in Asia, Africa, and Europe, ranging from war-torn countries to key political allies, as it continues to negotiate trade deals with the countries ahead of a new August 1 deadline.  Correspondent Josh Boak has the latest on the tariffs and for some countries what they can look like.   Musk's Party Plans Shares of Tesla tanked nearly 7 percent on Monday on the news that Elon Musk is planning to form a new political party in America.  Correspondent Rich Johnson reports the Tesla and SpaceX owner is also laying the foundation's planks for his new party, to include pro-Second Amendment and pro-Bitcoin positions.   Border Station Shooting A man armed with an assault rifle opened fire at a Border Patrol facility in Southern Texas, in what Fox News is reporting was a planned attack.  Correspondent Sagar Meghani has the story - audio courtesy of KGTV San Diego, California.   Chantal Turns Deadly Floodwaters in North Carolina created by Chantal have turned deadly.  Correspondent Mike Hempen reports.   Finally  A new report on kids is painting a disturbing picture.  Correspondent Haya Panjwani reports on a physical and mental health study tracking two decades of America's youth.   Learn more about your ad choices. Visit podcastchoices.com/adchoices

Welcome to another episode of Questions From ItaFootPod Patrons where you, our patrons, decide what the show is about by sending in your questions. Topics include: Is there a Civil War at Inter Milan with Lautaro Martinez vs Hakan Calhanoglu? Will Jonathan David be a top or a flop at Juventus? How can Antonio Conte's Napoli surpass the Diego Maradona side? Is Alessandro Del Piero underrated and better than Francesco Totti and Roberto Baggio? Which current Italian youngsters are good enough today to play for the Azzurri? And much, much more. Thank you Ahmed K, Saigonese, Andrew B, Leo, Mike, David B, Gianmarco P, Marty G, Mario S, Jack H, Daniel B, Gabor, CJ B and Adamo P for sending in your questions this week. This is an extra free bonus Q & A episode of The Italian Football Podcast which is available on Spotify, Apple Podcasts and YouTube podcasts. To listen to this & all other full episodes of The Italian Football Podcast (and support the show), go to Patreon.com/TIFP OR now also available on Spotify OR YouTube Memberships and sign up. Your support makes The Italian Football Podcast possible. Follow us: Twitter, Facebook, Instagram, YouTube Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode Adam and Alexandra open with some discussion on the latest news, including the release of 14 political prisoners in Belarus, repressions taking place in Azerbaijan, Romania and Georgia. For the main deep dive, Alexandra and Nina continue on the Georgian theme by speaking with Teona Macharashvili, co-founder and board member of Caucasus Open Space, and a committed pro-democracy activist, to unpack the latest developments in Georgia. Teona shares powerful first-hand insights from the ongoing protests, which have now continued for over 200 days.In the exclusive bonus segment – available to our Patrons - Teona sheds light on recent cuts to US foreign aid and what they mean for civil society and human rights defenders on the ground in Georgia. Listen to the bonus content here: https://www.patreon.com/posts/episode-228-132340122Further reading:Repression in Azerbaijan - An interview with Cesare FigariBarberis: https://neweasterneurope.eu/2025/06/24/repression-in-azerbaijan/The 2024 Georgian elections and their geopolitical implications, Vakhtang Maisaia:https://neweasterneurope.eu/2025/05/05/the-2024-georgian-elections-and-their-geopolitical-implications/History rhymes: intellectual resistance and state repression in Georgia, Tamar Gamkrelidze:https://neweasterneurope.eu/2025/03/24/history-rhymes-intellectual-resistance-and-state-repression-in-georgia/Sign up for our weekly newsletter – Brief Eastern Europe:www.briefeasterneurope.eu

On Tuesday's Football at Four on 97.3 ESPN South Jersey, Inside the Birds' Adam Caplan takes an inside look at perhaps the biggest Eagles challenger for the NFC Championship in 2025 during our daily segment.► Sign up for our newsletter! • Visit http://eepurl.com/hZU4_n► Sky Motor Cars • Visit https://www.skymotorcars.com and tell them Adam and Geoff sent you!► Stretch Zone • Visit https://www.stretchzone.com and sign up for your free 30-minute stretch and start feeling better!!SUBSCRIBE TO OUR PATREON CHANNEL FOR EXCLUSIVE, BONUS CONTENT: https://www.patreon.com/insidethebirds Follow the Hosts!► Follow our Podcast on Twitter: https://twitter.com/InsideBirds► Follow Geoff Mosher on Twitter: https://twitter.com/geoffpmosher► Follow Adam Caplan on Twitter: https://twitter.com/caplannfl► Follow Andrew DiCecco on Twitter: https://twitter.com/andrewdiceccoHow to access our FULL Podcast:APPLE: https://podcasts.apple.com/us/...SPREAKER: https://www.spreaker.com/user/...NFL insider veterans take an in-depth look that no other show can offer! Be sure to subscribe to stay up to date with the latest news, rumors, and discussions.For more, be sure to check out our official website: https://www.insidethebirds.com.

#ThisMorning on #BRN | #Wellness | #2083 | #Human #Therapists Surpass #ChatGPT in Delivering #Cognitive #Behavioral #Therapy | Esha Aneja, California Northstate College of Medicine | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #Wellness and #More - #Everyday

Without the power of the Holy Spirit and the Word there is simply no way to get ahead of the coming super spreading and self replicating MRNA technology!  The righteousness of the blameless shall rectify and make plain their way and keep it straight, but the wicked shall fall by their own wickedness. 6 The righteousness of the upright [their rectitude in every area and relation] shall deliver them, but the treacherous shall be taken in their own iniquity and greedy desire.

In today's Tech3 from Moneycontrol, we dive into how RCB's historic IPL win is pushing up its brand value, and what that means for Virat Kohli. We also track UPI's meteoric rise as it threatens to overtake Visa in daily transactions. Plus, Zepto puts its IPO on hold till 2026 amid internal challenges, and OfBusiness gears up for its $1 billion IPO by expanding deeper into manufacturing and apparel. Tune in for more startup and tech updates.

The NFL is a year-to-year league, so is Brock Purdy set to overtake Jalen Hurts in the QB rankings this year?

Rob Nishihara is the co-creator of Ray, the open-source software now used by OpenAI, Amazon, DeepSeek, and Nvidia as part of the essential stack for building AI at scale. Rob offers a rare insider's view of the bottlenecks, breakthroughs, and practical limits shaping AI today. The discussion ranges from the philosophical to the technical—covering synthetic data, future policy, career resilience, and how AI might ultimately make us think better, not just faster. — For a deeper dive into these insights and more, be sure to listen to the full episode of the Onward podcast. Have questions or feedback about this episode? Drop us a note at Onward@Fundrise.com.  Onward is hosted by Ben Miller, co-founder and CEO of Fundrise. Podcast production by The Podcast Consultant. Music by Seaplane Armada.  About Fundrise  With over 2 million users, Fundrise is America's largest direct-to-investor alternative asset investment platform. Since 2012, our mission has been to build a better financial system by empowering the individual. We make it easier and more efficient than ever for anyone to invest in institutional-quality private alternative assets — all at the touch of a button.  Please see fundrise.com/oc for more information on all of the Fundrise-sponsored investment funds and products, including each fund's offering document(s).  Want to see the specific assets that make up and power Fundrise portfolios? Check out our active and past projects at www.fundrise.com/assets.

5.15.25 Hour 1, Kevin Sheehan reacts to and gives his thoughts on the Commanders schedule official release. Kevin Sheehan talks about the Commanders win total for the 2025 season which is at 9.5 and asks callers whether the Commanders can surpass it.

Gem Of the Day (G.O.D.) about Philippians 4:4-7

Plus - Microsoft and OpenAI may be renegotiating their partnership; Apple reportedly plans to hike prices of upcoming iPhones Learn more about your ad choices. Visit podcastchoices.com/adchoices

This latest podcast episode is a bit of an experiment, as we've utilised NotebookLM to transform one of our recent articles that analyses catastrophe bond issuance through April 25th 2025 into an audio podcast episode. Even with a few days to run of the fourth month of the year, catastrophe bond market issuance in 2025 is already on-track to set a new record for issuance through May, as the pipeline of new cat bond deals continues to build. With new catastrophe bond issuances that have completed and settled this week, the total cat bond issuance tracked in the Artemis Deal Directory has already reached almost $8.25 billion this year. But, impressively, the pipeline of new cat bonds slated for completion and settlement up to and including the month of May so far has now reached $3.82 billion. As a result, our forecast for catastrophe bond issuance across Rule 144A cat bonds and the privately placed deals we've tracked so far in 2025 has now reached $12.07 billion, with all of that issuance currently scheduled to settle by the end of the week of May 19th at this stage. Please note, dates of settlement for new catastrophe bond issues can change, so the forecasts could adjust over the coming weeks, but the main story does not change.  The catastrophe bond market remains on record-setting pace and further growth of the outstanding cat bond market is anticipated.

AP correspondent Ed Donahue reports a measles outbreak is growing.

7:00 HOUR: Is Michigan basketball poised to surpass MSU? Are the Tigers a better team now than last year's playoff team?

4/9/25 -A Red Wings funeral, Michigan basketball might be poised to surpass MSU, The Tigers are thriving instead of just surviving

Send us a textToday, I'm thrilled to be sitting down with Kate Torrance - the VP and Head of Brand, Content & Communications at SickKids Foundation. With over two decades of experience in advertising and communications, Kate has been instrumental in shaping SickKids' brand strategy and maintaining its position as Canada's top charity brand.At SickKids Foundation, Kate leads the charge in driving awareness and raising funds for The Hospital for Sick Children in Toronto, ranked as the number two pediatric hospital globally. Her expertise has been crucial in launching groundbreaking initiatives like the globally recognized VS brand platform and the innovative Precision Child Health approach.Before joining SickKids, Kate honed her skills at top-tier advertising agencies, where she led national campaigns for renowned brands such as Budweiser, Starbucks, and Coca-Cola. Her diverse experience and passion for making a difference in children's lives make her a fascinating guest for our podcast.Today, we'll explore Kate's journey in brand strategy, her role in SickKids' philanthropic efforts, and how she's helping to shape the future of pediatric healthcare through innovative communication strategies. So, let's dive in and learn from one of the brightest minds in cause-driven marketing and communications!BRANDING MATTERS is one of the 40 Best Branding Podcasts worldwide. It's one of the 17 Branding Podcasts Worth Your Time in 2025. And it's one of the 20 Great Podcasts to Grow Your Brand. Thanks for listening! If you enjoyed this episode, please leave a 5-star rating along with a brief review. And don't forget to order your BADASS T-shirt here.About MeHey there, I'm Joelly - the Branding Badass. My BADASS superpower is helping you build a brand that matters. From branded merch to keynote speaking, when you work with me, you get results! Need help telling your brand story? Learn more here.Let's stay connected!instagram - @Branding_BadasslinkedIn - Joelly Goodsonwebsite - BAMKO.NET

Abby Hohlbein is a 410-sprint racer who, when not carving up the dirt or the track, is assisting students with disabilities in the classroom, chasing a little white ball around the links, and preparing for college with an amazing major in Motorsports Marketing and Management.Not one to shy away from hard work or getting her hands dirty in the shop, Abby acknowledges the challenges of managing partners and sponsors in the industry by emphasizing the importance of being valuable to each partner, maintaining a good image andbeing accessible to fans while balancing her responsibilities on being a positive role model for young female race car drivers.Connect with Abby here:Website: www.abbyhracing.comFacebook: https://www.facebook.com/AbbyHohlbeinRacingX: @AbbyHohlbeinInstagram: www.instagram.com/abbyhohlbeinracing/Connect with Red Line Oil:www.redline.comConnect with Mecum Auctions:www.Mecum.comConnect with JP Emerson: www.jpemerson.comFor more podcasts on cars check out Ford Mustang The Early Years Podcast at www.TheMustangPodcast.com, at Apple Podcasts or anywhere you get your podcastsFor more information about sponsorship or advertising on The JP Emerson Show or podcast launch services, contact Doug Sandler at doug@turnkeypodcast.com or visit www.turnkeypodcast.comAbby Hohlbein is a 410-sprint racer who, when not carving up the dirt or the track, is assisting students with disabilities in the classroom, chasing a little white ball around the links, and preparing for college with an amazing major in Motorsports Marketing and Management.Not one to shy away from hard work or getting her hands dirty in the shop, Abby acknowledges the challenges of managing partners and sponsors in the industry by emphasizing the importance of being valuable to each partner, maintaining a good image, and being accessible to fans while balancing her responsibilities to be a positive role model for young female race car drivers.

The search for survivors continues in Myanmar as the number of deaths rises to more than 1600. The UN pleads for the Burmese military to stop attacking rebels. Also: Mexico tackles its country's obesity problem.

Sixers lose to the Heat 118-95 and fall to 23-51 on the season.Philadelphia 76ers vs Miami Heat Postgame Live Show (2024-25) - Regular Season Game 74 #Sixers #76ers #Heat #NBAADVERTISE WITH US:https://forms.gle/BHCmXV9XZs41CKPGACHECK OUT THE NEW MERCH: https://phillytakewithrb.com/Playback: https://www.playback.tv/phillytakewithrbPhilly Take Discord: https://discord.gg/vEXh2AqpVenmo: https://venmo.com/phillytakewithrbCashApp: https://cash.app/$phillytakewithrbSubscribe to Philly Take with RB on YouTube: https://www.youtube.com/channel/UCZ6xo8_BSzZJVYfWEqEt1GwINSTA: https://www.instagram.com/rbphillytake/TWITTER: https://twitter.com/RBPhillyTake

WarRoom Battleground EP 734: Gold Futures Surpass 3100 Dollars

It's the perfect time to revisit one of our more popular episodes. Taylor Swift and Beyoncé are still at the top of the music industry despite the newer artists that do well on streaming and TikTok. That said, can today's new class of stars ever match that same level of superstardom? .In this episode, I'm joined by Tati Cirisano from MIDiA Research to explore how artists like Billie Eilish, Dua Lipa, and Bad Bunny are navigating the ever-changing music landscape. What does it take to break through the noise, and is music stardom evolving into something completely different?Let's get into it02:00 Streaming's Impact on Music Industry07:06 The impact of streaming and TikTok11:09 Olivia Rodrigo's Streaming vs Sales15:03 Dua Lipa, Doja Cat, SZA23:23 Morgan Wallen, Bad Bunny30:28 "Music Industry Aspirations and Realities"33:39 Emerging Artists: Success Through Unique RootsTrapital Summit tickets are on sale! Super early bird discount until April 30. Register here.This episode is presented by State Farm, the home for your small business needs. Like a good neighbor, State Farm is there.Make sure you check out TechCrunch's flagship podcast, Equity.Listen in for our Chartmetric Stat of the Week.If you enjoy Trapital, please rate and review on your favorite podcast platform!

Get an easy $200 from Melio for making your first payment! (Affiliate link. Terms below) https://affiliates.meliopayments.com/travelonpointsteam Episode Description This week American Express and Hilton released increased offers on most of their cobranded cards. Specifically the Surpass and the no annual fee card have great welcome offers which include a free night cert. These certs are so valuable, but is now the right time to pick up one of these cards?   In other news American Airlines is trialing free WiFi. Is free internet on all airplanes in our future? We also discuss a Capital One Discover takeover strategy, Flying Blue's march promos, credit card art, Chase Freedom's extra category, the evolution of pod hotels and why Sugarloaf Mountain in Rio is some cool S.   Episode Guide 0:00 Credit card “art” 1:14 Flying Blue's March promo awards 3:23 The evolution of pod hotels - Worth a try? 4:30 What it is like staying in a pod hotel 5:36 American Airlines is trialing free WiFi 7:40 Increased offers for Hilton - Free nights are back! 9:43 Chase Freedom's birthday bonus category 10:56 Capital One's Discover takeover - Application strategy? 12:11 Will the Discover brand last long term? 14:17 Capital One Venture's better 100K offer 15:30 Barclays big glitch - Double accounts for everyone! 17:21 Cool S - Sugarloaf Mountain in Rio Links Credit card art - https://x.com/z72917378/status/1895587820577964421?s=46 Flying Blue - https://travel-on-points.com/flying-blue-promo-awards/ Pod hotels - https://x.com/interesting_aIl/status/1893685309138726922 AA WiFi trial - https://milestomemories.com/american-airlines-to-offers-complimentary-wi-fi-soon/ Discover strategy - https://travel-on-points.com/should-you-get-a-discover-card/ 100K Venture - https://milestomemories.com/100k-bonus-for-capital-one-venture-card/ Barclays glitch - https://travel-on-points.com/barclays-approving-two-credit-cards/   Enjoying the podcast? Please consider leaving us a positive review on your favorite podcast platform! You can also connect with us anytime at podcast@milestomemories.com.  You can subscribe on Apple Podcasts, Google Play, Spotify, TuneIn, Pocket Casts, or via RSS. Don't see your favorite podcast platform? Please let us know!

While everyone is freaking out, we break down why Mahomes will still surpass Tom Brady as the G.O.A.T.; we explain why this year's halftime show was even worse than the game itself; and we react to the best and worst big game moments and commercials. Ep.695 - - - Today's Sponsors: Lumen - Take the next step to improving your health: go to https://lumen.me/BOOSTER to get 20% off your Lumen.